06-22 InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. CI
06-22 InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds AQ
06-15 InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition MT
06-15 InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition AQ
06-15 InterCure Ltd. acquired 50% stake of Botanico Ltd. CI
06-15 InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd. CI
05-01 InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow AQ
05-01 InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-04 InterCure Receives Noncompliance Notice From Nasdaq MT
03-04 InterCure receives Nasdaq notification regarding minimum bid requirement RE
03-04 InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement AQ
02-19 InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million RE
02-19 InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million AQ
12-19 InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court RE
11-03 Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd. CI
11-03 InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd CI
11-03 InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation AQ
08/10/25 InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
08/10/25 Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow RE
08/10/25 InterCure Ltd H1 2025 revenue NIS 130 million RE
08/10/25 InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow AQ
19/09/25 InterCure to Acquire Cannabis Brand Botanico in Two-Phase Deal MT
19/09/25 Intercure to buy ISHI, gaining access to premium U.S. cannabis tech and brands RE
19/09/25 InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands AQ
19/09/25 InterCure Ltd. agreed to acquire Botanico Ltd. for ILS 25.3 million. CI
No results match your criteria